Codexis Shares Outstanding 2009-2021 | CDXS

Codexis shares outstanding from 2009 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Codexis Annual Shares Outstanding
(Millions of Shares)
2020 59
2019 57
2018 52
2017 46
2016 41
2015 39
2014 38
2013 38
2012 37
2011 36
2010 25
2009 3
2008 2
Codexis Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 64
2021-03-31 64
2020-12-31 59
2020-09-30 59
2020-06-30 59
2020-03-31 59
2019-12-31 57
2019-09-30 61
2019-06-30 55
2019-03-31 54
2018-12-31 52
2018-09-30 54
2018-06-30 53
2018-03-31 48
2017-12-31 46
2017-09-30 48
2017-06-30 47
2017-03-31 41
2016-12-31 41
2016-09-30 42
2016-06-30 42
2016-03-31 40
2015-12-31 39
2015-09-30 41
2015-06-30 39
2015-03-31 39
2014-12-31 38
2014-09-30 38
2014-06-30 38
2014-03-31 39
2013-12-31 38
2013-09-30 38
2013-06-30 38
2013-03-31 38
2012-12-31 37
2012-09-30 37
2012-06-30 36
2012-03-31 36
2011-12-31 36
2011-09-30 36
2011-06-30 36
2011-03-31 35
2010-12-31 25
2010-09-30 34
2010-06-30 27
2010-03-31 3
2009-12-31 3
2009-09-30 3
2009-06-30 3
2009-03-31 3
2008-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.653B $0.069B
Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis? proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29